Phase 1 Selected Companies Announced for Free Access to Arterial Live Course Benefits!
"Artery Open Class"Since the official launch of the call for submissions on May 17, it has attracted significant attention from numerous innovative medical enterprises. As of May 30, the VCBeat VB jury evaluated the applicant companies across four dimensions: product/service introduction, business model, case innovation, and case effectiveness. This“Artery Open Course”Three companies meeting the requirements have been selected; the list is hereby announced as follows:
Dongmai Medical was established in 2019 through a joint initiative by the Southeast University Suzhou Medical Device Research Institute and an industry-leading team. Located in the Suzhou Life Health Town, its facility covers a construction area of over 2,500 square meters. Leveraging the expertise of Southeast University, Dongmai Medical specializes in compliance-driven design, development, and engineering translation for medical devices. The company operates two production lines—one for active medical devices and another for sterile medical devices—and has established a benchmark-quality management system in accordance with ISO 13485 standards. Additionally, Dongmai Medical has built an in-house testing platform compliant with the ISO/IEC 17025 framework and assembled elite teams specializing in regulatory registration, quality systems, and clinical affairs to provide one-stop services for medical device enterprises, ranging from R&D and design to mass production.
Zhilan Health is a medical technology company specializing in the research, development, and application of digital therapeutics. It provides end-to-end R&D and related services for disease-focused digital medical products to researchers and companies across the industry value chain. These services encompass digital therapeutics CDMO and full-process solutions, including medical protocol design, product design and development, pilot-scale translation, clinical trials, regulatory registration services, commercial operations, and real-world evidence studies.
Guangzhou Shijing Medical Software Co., Ltd. (“Shijing Medical”) is a leading digital technology company in China’s digital ophthalmology sector. The company offers innovative solutions such as “Duobaoshi” for the treatment of strabismus and amblyopia in children and adolescents, and “Beibeile” for myopia prevention and control. Its portfolio of independently developed products includes a telemedicine platform for vision therapy, VR wearable smart devices, eye-tracking technology, an AI-based visual acuity screening system, and an AI-powered intelligent solution planning system. The company has successfully completed project approvals and acceptances from the Ministry of Science and Technology of China, the Guangzhou Municipal Science and Information Technology Bureau, and the Tianhe District Science and Information Technology Bureau, and has maintained its status as a National High-Tech Enterprise for nine consecutive years. It has obtained Class II Medical Device Registration Certificates issued by the Chinese regulatory authorities, CE certification, ISO 13485 quality management system certification (by TÜV SÜD), Intellectual Property Management System certification, and filing for Classified Protection of Cybersecurity. Additionally, it has been granted 18 patents. Shijing Medical’s services cover more than 30 provinces, autonomous regions, and municipalities across China, and it has established stable cooperative relationships with over 2,000 hospitals.
As a launch benefit for the new platform, all three companies willFreeAcquire High-Value"Artery Open Course"Promotional resources, includingLive-streamed courses (multiple sessions scheduled according to the enterprise’s specific needs), along with targeted dissemination through VCBeat’s media matrix, precision community channels, and industry networks.。
If you would like to learn more,VCBeat Open Course: Scan the QR code below to join., our assistant will serve you as soon as possible.
